An in-vitro thromboelastometry test for anti-Xa drug molecules: = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
Erlangen ; Nürnberg
[2019]
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 171 Seiten Illustrationen, Diagramme 21 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV045552573 | ||
| 003 | DE-604 | ||
| 005 | 20190411 | ||
| 007 | t | ||
| 008 | 190410s2019 gw a||| m||| 00||| eng d | ||
| 015 | |a 19,H05 |2 dnb | ||
| 016 | 7 | |a 1182063659 |2 DE-101 | |
| 020 | |c Broschur | ||
| 035 | |a (OCoLC)1121483321 | ||
| 035 | |a (DE-599)DNB1182063659 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE | ||
| 049 | |a DE-29T |a DE-29 |a DE-355 | ||
| 084 | |a 610 |2 sdnb | ||
| 084 | |a 540 |2 sdnb | ||
| 100 | 1 | |a Holtappels, Jens M. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a An in-vitro thromboelastometry test for anti-Xa drug molecules |b = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |c vorgelegt von Jens M. Holtappels |
| 246 | 1 | 3 | |a Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| 246 | 1 | 1 | |a Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| 264 | 1 | |a Erlangen ; Nürnberg |c [2019] | |
| 300 | |a 171 Seiten |b Illustrationen, Diagramme |c 21 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c Friedrich-Alexander-Universität Erlangen-Nürnberg |d 2019 | ||
| 650 | 0 | 7 | |a Test |0 (DE-588)4059549-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Blutgerinnung |0 (DE-588)4007275-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gerinnungsfaktor Xa |0 (DE-588)4156838-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Blutgerinnung |0 (DE-588)4007275-7 |D s |
| 689 | 0 | 1 | |a Gerinnungsfaktor Xa |0 (DE-588)4156838-2 |D s |
| 689 | 0 | 2 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | 3 | |a Test |0 (DE-588)4059549-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u http://d-nb.info/1182063659/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936519&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030936519 | ||
Datensatz im Suchindex
| _version_ | 1804179528562507776 |
|---|---|
| adam_text | ACKNOWLEDGEMENTS
..................................................................................................
V
TABLE
OF
CONTENTS
.....................................................................................................
IX
LIST
OF
ABBREVIATIONS
.............................................................................................
XIII
1.
INTRODUCTION
............................................................................................................
1
2.
HEMOSTASIS
............................................................................................................
5
2.1
PRIMARY
HEMOSTASIS
.......................................................................................
5
2.2
SECONDARY
HEMOSTASIS...................................................................................
8
2.2.1
INITIATION
PHASE
........................................................................................
9
2.2.2
AMPLIFICATION
PHASE
...............................................................................
11
2.2.3
PROPAGATION
PHASE
................................................................................
12
2.2.4
THE
CONTACT
PATHWAY
.............................................................................
14
2.2.5
THE
ROLE
OF
FACTOR
XA
IN
COAGULATION
....................................................
17
2.3
ANTICOAGULATION
.............................................................................................
17
2.3.1
SERINE
PROTEASE
INHIBITORS
......................................................................
17
2.3.2
THE
PROTEIN
C
SYSTEM
............................................................................
19
2.3.3
FIBRINOLYSIS
.............................................................................................
22
3.
COAGULATION
ASSAYS
............................................................................................
25
3.1
GLOBAL
ASSAYS
...............................................................................................
25
3.1.1
PROTHROMBIN
TIME
..................................................................................
25
3.1.2
ACTIVATED
PARTIAL
THROMBOPLASTIN
TIME
.................................................
26
3.2
ROTATIONAL
THROMBOELASTOMETRY....................................................................
27
3.2.1
PHYSICAL
BASICS
OF
THROMBOELASTOGRAPHY
...............................................
27
3.2.2
THROMBOELASTOGRAPHY
AND
ROTATIONAL
THROMBOELASTOMETRY
RESULT
PARAMETERS
.........................................................................................................
31
3.2.3
ROTATIONAL
THROMBOELASTOMETRY
ASSAYS
................................................
32
4.
CRYOPELLETIZATION
..................................................................................................
35
4.1
DROPLET
GENERATION
AND
FREEZING
.................................................................
36
4.2
LYOPHILIZATION
................................................................................................
40
5.
MATERIALS
AND
METHODS........
................................................................................
45
5.1
MATERIALS
.......................................................................................................
45
5.1.1
COAGULATION
FACTOR
XA
...........................................................................
45
5.1.2
RIVAROXABAN
...........................................................................................
46
5.1.3
ROTATIONAL
THROMBOELASTOMETRY
.............................................................
46
5.1.4
EXCIPIENTS
AND
REAGENTS
........................................................................
47
5.2
METHODS
........................................................................................................
48
5.2.1
ROTEM
DELTA
.........................................................................................
48
5.2.2
CRYOPELLETIZATION
....................................................................................
50
5.2.3
FREEZE-DRYING
.....................................................................
51
5.2.4
FACTOR
XA
CHROMOGENIC
ASSAY
..............................................................
51
5.2.5
PEGYLATION
OF
FACTOR
XA
........................................................................
52
5.2.6
PEGYLATED
FACTOR
XA
ROTEM
ASSAY
.....................................................
53
5.2.7
RESISTANCE
MEASUREMENT
......................................................................
54
5.2.8
ELECTROSTATIC
CHARGE
MEASUREMENT
........................................................
55
5.2.9
SDS-PAGE
............................................................................................
55
5.2.10
SIZE
EXCLUSION
CHROMATOGRAPHY
.........................................................
55
5.2.11
DIFFERENTIAL
SCANNING
CALORIMETRY
.......................................................
56
5.2.12
KARL-FISCHER
TITRATION
...........................................................................
56
5.2.13
SCANNING
ELECTRON
MICROSCOPY
...........................................................
56
6.
RESULTS
AND
DISCUSSION
......................................................................................
57
6.1
DESIGN
OF
AN
ANTI-XA
ROTEM
TEST
...............................................................
57
6.2
DEVELOPMENT
OF
A
PEG-XA
REAGENT
.............................................................
58
6.2.1
EXCIPIENT
SELECTION
.................................................................................
58
6.2.2
FACTOR
XA
PEGYLATION
............................................................................
71
6.2.3
YIELD
DETERMINATION................................................................................
76
6.2.4
PEGYLATION
YIELD
ENHANCEMENT
.............................................................
82
6.2.5
PEG-XA
CRYOPELLET
PRODUCTION
AND
TESTING
...........................................
91
6.2.6
STABILITY
TESTING
......................................................................................
97
6.2.7
CONCLUSIONS
.........................................................................................
104
6.3
DEVELOPMENT
OF
A
COAGULATION
ACTIVATOR
....................................................
105
6.3.1
COMPARISON
OF
BLOOD
COAGULATION
ACTIVATORS
.......................................
105
6.3.2
PRODUCTION
AND
TESTING
OF
SILICA
CRYOPELLETS
.......................................
114
6.3.3
CONCLUSIONS
.........................................................................................
122
6.4
PEG-XA
AND
SILICA
IN
A
SINGLE
CRYOPELLET
...................................................
123
6.4.1
INITIAL
CONSIDERATIONS
............................................................................
123
6.4.2
PRODUCTION
AND
CHARACTERIZATION
OF
THE
COMBINED
CRYOPELLETS
...........
124
6.4.3
CONCLUSIONS
.........................................................................................
130
6.5
REDUCTION
OF
ELECTROSTATIC
CHARGE
..............................................................
131
6.5.1
RELATIVE
HUMIDITY
APPROACH
.................................................................
131
6.5.2
FEW-LAYER
GRAPHENE
APPROACH
...........................................................
140
6.5.3
GOLD
APPROACH
.....................................................................................
147
6.5.4
CONCLUSIONS
.........................................................................................
151
7.
CONCLUSION
.........................................................................................................
153
8.
ZUSAMMENFASSUNG
............................................................................................
157
9.
BIBLIOGRAPHY
.......................................................................................................
161
|
| any_adam_object | 1 |
| author | Holtappels, Jens M. |
| author_facet | Holtappels, Jens M. |
| author_role | aut |
| author_sort | Holtappels, Jens M. |
| author_variant | j m h jm jmh |
| building | Verbundindex |
| bvnumber | BV045552573 |
| ctrlnum | (OCoLC)1121483321 (DE-599)DNB1182063659 |
| discipline | Chemie / Pharmazie Medizin |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02189nam a2200493 c 4500</leader><controlfield tag="001">BV045552573</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190411 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">190410s2019 gw a||| m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">19,H05</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1182063659</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="c">Broschur</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1121483321</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1182063659</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">540</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Holtappels, Jens M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">An in-vitro thromboelastometry test for anti-Xa drug molecules</subfield><subfield code="b">= Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren</subfield><subfield code="c">vorgelegt von Jens M. Holtappels</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren</subfield></datafield><datafield tag="246" ind1="1" ind2="1"><subfield code="a">Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen ; Nürnberg</subfield><subfield code="c">[2019]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">171 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">21 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">Friedrich-Alexander-Universität Erlangen-Nürnberg</subfield><subfield code="d">2019</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Test</subfield><subfield code="0">(DE-588)4059549-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Blutgerinnung</subfield><subfield code="0">(DE-588)4007275-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gerinnungsfaktor Xa</subfield><subfield code="0">(DE-588)4156838-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Blutgerinnung</subfield><subfield code="0">(DE-588)4007275-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Gerinnungsfaktor Xa</subfield><subfield code="0">(DE-588)4156838-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Test</subfield><subfield code="0">(DE-588)4059549-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://d-nb.info/1182063659/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936519&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030936519</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV045552573 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:21:18Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030936519 |
| oclc_num | 1121483321 |
| open_access_boolean | |
| owner | DE-29T DE-29 DE-355 DE-BY-UBR |
| owner_facet | DE-29T DE-29 DE-355 DE-BY-UBR |
| physical | 171 Seiten Illustrationen, Diagramme 21 cm |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| record_format | marc |
| spelling | Holtappels, Jens M. Verfasser aut An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren vorgelegt von Jens M. Holtappels Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren Erlangen ; Nürnberg [2019] 171 Seiten Illustrationen, Diagramme 21 cm txt rdacontent n rdamedia nc rdacarrier Dissertation Friedrich-Alexander-Universität Erlangen-Nürnberg 2019 Test (DE-588)4059549-3 gnd rswk-swf Blutgerinnung (DE-588)4007275-7 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Gerinnungsfaktor Xa (DE-588)4156838-2 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Blutgerinnung (DE-588)4007275-7 s Gerinnungsfaktor Xa (DE-588)4156838-2 s Arzneimittel (DE-588)4003115-9 s Test (DE-588)4059549-3 s DE-604 B:DE-101 application/pdf http://d-nb.info/1182063659/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936519&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Holtappels, Jens M. An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren Test (DE-588)4059549-3 gnd Blutgerinnung (DE-588)4007275-7 gnd Arzneimittel (DE-588)4003115-9 gnd Gerinnungsfaktor Xa (DE-588)4156838-2 gnd |
| subject_GND | (DE-588)4059549-3 (DE-588)4007275-7 (DE-588)4003115-9 (DE-588)4156838-2 (DE-588)4113937-9 |
| title | An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| title_alt | Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| title_auth | An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| title_exact_search | An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| title_full | An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren vorgelegt von Jens M. Holtappels |
| title_fullStr | An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren vorgelegt von Jens M. Holtappels |
| title_full_unstemmed | An in-vitro thromboelastometry test for anti-Xa drug molecules = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren vorgelegt von Jens M. Holtappels |
| title_short | An in-vitro thromboelastometry test for anti-Xa drug molecules |
| title_sort | an in vitro thromboelastometry test for anti xa drug molecules ein in vitro thromboelastometrie test zum nachweis von direkten faktor xa inhibitoren |
| title_sub | = Ein in-vitro Thromboelastometrie-Test zum Nachweis von direkten Faktor Xa Inhibitoren |
| topic | Test (DE-588)4059549-3 gnd Blutgerinnung (DE-588)4007275-7 gnd Arzneimittel (DE-588)4003115-9 gnd Gerinnungsfaktor Xa (DE-588)4156838-2 gnd |
| topic_facet | Test Blutgerinnung Arzneimittel Gerinnungsfaktor Xa Hochschulschrift |
| url | http://d-nb.info/1182063659/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030936519&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT holtappelsjensm aninvitrothromboelastometrytestforantixadrugmoleculeseininvitrothromboelastometrietestzumnachweisvondirektenfaktorxainhibitoren AT holtappelsjensm eininvitrothromboelastometrietestzumnachweisvondirektenfaktorxainhibitoren |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis